Logo
About usInnovation CMChallengesEuropaEntrepreneurshipR&D&I SearchAgentsEventsReports
en
USE OF A COMPOSITION IN THE PRODUCTION OF A DIALYSIS SOLUTION FOR THE TREATMENT OF CEREBROVASCULAR DISEASES BY MEANS OF PERITONEAL DIALYSISCM Patents

The invention relates to the use of an isotonic composition buffered with lactate/phosphate in a physiologically acceptable pH range (6 - 7.5), with low concentrations of glutamate and a physiological or smaller concentration of glucose, in the production of a peritoneal dialysis solution for the acute treatment of stroke and other cerebrovascular diseases. The application of this dialysis solution in the peritoneal cavity significantly reduces the volume of cerebral infarction associated with the occlusion of the middle cerebral artery and, consequently, the associated neurological damage. The invention is suitable for use in biomedicine in cerebrovascular pathologies, including hemorrhagic or cerebral ischemic stroke.

Datos clave

CategoríaInvención

Índice de la ficha

Updated at
05/11/2026
Numero publicacion
EP.2759300.A2
Fecha publicacion
30/07/2014
Anio publicacion
2014
Numero solicitud
EP20120814911

En detalle

Reivindicaciones

1. Use of an isotonic composition buffered to a physiologically acceptable pH in the preparation of a dialysis solution for the treatment of a cerebrovascular disease by means of peritoneal dialysis. 2. Use according to claim 1, wherein the composition comprises electrolyte concentrations of 110 to 150 mEq/L of sodium ion, of 0 to 5 mEq/L of potassium ion, of 0 to 2 mEq/L of magnesium ion, of 0 to 6 mEq of calcium ion and of 80 to 150 mEq/L of chloride ion. 3. Use according to any of claims 1-2, where the pH is between 6 and 7.5 and it is buffered by means of a mixture of lactic acid and phosphate. 4. Use according to claim 3, wherein the lactic acid concentration is 0 to 3.5 mmol/L. 5. Use according to claim 4, wherein the phosphate concentration is 10 mmol/L. 6. Use according to any of the preceding claims, wherein the composition contains a glucose concentration of between 0.5 and 2.0 g/L. 7. Use according to claim 6, wherein the glucose concentration is 0.75 g/L. 8. Use according to claim 6, wherein the glucose concentration is 1.5 g/L. 9. Use according to any of the preceding claims, wherein the composition contains a glutamate concentration equal to or less than 200 µM. 10. Use according to any of the preceding claims, wherein the composition contains dextrin. 11. Use according to any of the preceding claims, where the cerebrovascular disease is cerebral ischemia. 12. Use according to claim 9, where the cerebral ischemia is acute or chronic cerebral ischemia and is one of the following diseases: transient ischemic attack, traumatic brain injury, cerebral ischemic stroke or cerebral hemorrhagic stroke.

Etiquetas

Inventores
Mora Sánchez María ÁngelesMora Sánchez, María ÁngelesLizasoaín Hernández IgnacioLizasoaín Hernández, IgnacioSánchez-Prieto Borja JoséSánchez-Prieto Borja, JoséTorres Molina MagdalenaTorres Molina, MagdalenaGodino Alarcon María del CarmenGodino Alarcon, María del CarmenSobrado Sanz, MonicaSobrado Sanz MonicaGonzáles Romera Victor ManuelGonzáles Romera, Victor ManuelVivancos Mora, José AurelioVivancos Mora José AurelioMora Sanchez, Maria AngelesMora Sanchez Maria AngelesLizasoain Hernandez IgnacioLizasoain Hernandez, IgnacioSanchez-Prieto Borja, JoseSanchez-Prieto Borja JoseGodino Alarcon, Maria del CarmenGodino Alarcon Maria del CarmenGonzales Romera, Victor ManuelGonzales Romera Victor ManuelVivancos Mora Jose AurelioVivancos Mora, Jose Aurelio
Solicitantes
Universidad Complutense de Madrid
Clasificacion ipc
A61K 31/ 198 A IA61K 31/ 7004 A IA61K 31/ 718 A IA61K 33/ 00 A IA61K 33/ 06 A IA61K 33/ 14 A IA61K 33/ 42 A IA61M 1/ 28 A IA61P 7/ 08 A I
Logo

Innovation CM
Challenges
Europa
Entrepreneurship
R&D&I Search
Agents
Events
Reports
About us
Contact
Give us your opinion
Cookies
Legal notice
Privacy

© Copyright Espacio Madrileño de Investigación e Innovación 2026